Article Text

PDF
Letter
Improving future studies in chronic pancreatitis: a paradigm shift in our understanding?
  1. Andrew D Hopper,
  2. Jennifer A Campbell
  1. Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield, UK
  1. Correspondence to Dr Andrew D Hopper, Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield, S102JF, UK; andydhopper{at}aol.com

Statistics from Altmetric.com

We read with interest the study by de la Iglesia-García et al1 The authors present a detailed, well-conducted meta-analysis of the efficacy of pancreatic enzyme replacement therapy (PERT) in patients with chronic pancreatitis (CP) who also have evidence of exocrine pancreatic insufficiency (EPI). Using level 1 evidence studies, the primary endpoint of fat absorption is shown to increase with PERT, with additional improvements shown in GI symptoms and quality of life. The authors should be commended for their work clarifying the beneficial use of PERT in this group of patients, but they and the preceding commentary by Windsor2 highlight the heterogenicity of the criteria used to diagnose CP and the greater need for a clear consensus to help target and guide dosing of PERT. Although a recent consensus to produce a mechanistic definition for …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.